top of page

Check the programme regularly for updates


Sunday 25 June



New regimens for TB and TPP to shape the future of TB treatment 

Chair: Daniela Maria Cirillo, Philip Supply


GL01  Samuel Schumacher, WHO, Geneva

Target Regimen Profiles (TRPs) for TB treatment - VIRTUAL

GL02  Francesca Conradie, WITS HEALTH, University of the Witwatersrand, South Africa

TB universal regimens; pros and cons for adults and pediatric population

GL03  Christian Lienhardt, French Institute for. Research on Sustainable Development (IRD), Montpellier

New regimens, new TBdrugs: what to expect? - VIRTUAL

GL04  Saskia Den Boon, WHO

Target Product Profiles for Tests for TB Treatment Monitoring and Optimization

Coffee Break

Student mini-symposium on new drugs and DR TB (5 min flash talks)

Chair: Stefan Niemann, Silva Tafaj


P38  Marco Schiuma , Department of Biomedical & Clinical Sciences "Luigi Sacco", Università degli Studi di Milano, Italy.

Rifampicin and isoniazid dosage adjustment according to TDM and acetylator status: a single centre prospective observational study  

P63  Jihad Snobre, Mycobacteriology Unit, Biomedical Sciences, Institute of Tropical Medicine (ITM), Antwerp

Exploring the impact of mutations in Rv0678 gene on bedaquiline resistance in Mycobacterium tuberculosis: insights from computational biostructural proteomics

P61  Ilariaa Iannucci, Universita Vita-Salute San Raffaele, Milan

In vitro susceptibility testing of GSK656 against Mycobacterium tuberculosis complex isolates to establish the epidemiological cut-off values and MIC distribution

P08  Emilie Rousseau, Molecular and Experimental Mycobacteriology, Research Center Borstel,

Mutation rates in strains of different Mycobacterium tuberculosis lineages associated with emergence of multi-drug resistant tuberculosis

P30  Darshaalini Nadarajan, National and Supranational Reference Laboratory for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany

Prospective evaluation of targeted next-generation sequencing of Mycobacterium tuberculosis complex strains in routine diagnostics in Germany.

P35  Virginia Batignani, San Raffaele Scientific Institute

Xpert MTB/XDR assay for the rapid diagnosis of TB resistance. A country wide cross sectional observational prospective study from Pakistan


Opening session

Chair: Daniela Maria Cirillo, Silva Tafaj


GL05 Opening Keynote  Silvia Bino, Head of Infectious Diseases, Institute of Public Health

High priority and emerging pathogens in Albania

GL06 Gertrud Meissner Award presented by S. Niemann

GL07 Gardner Middlebrook Award presented by BD


Monday 26 June



Host pathogens interaction in M tuberculosis 

Chair: Leen Rigouts, Matthias Merker


GL08  Margarida Saraiva, Department of Microbiology and Immunology, McGill University

Study of host pathogen interactions in TB by using an in clinico to in vitro to in vivo approach

GL09  Stephanie Boisson-Dupuis, Rockefeller University, NYC

Novel genetic etiologies in susceptibility to tuberculosis 

OR01  Sarah Danchuk, McGill University, Montreal,

Understudied and overlooked: Characterizing Mycobacterium orygis

OR02  Paolo Miotto, San Raffael Scientific Institute

Mycobacterial extracellular vesicles (MEVs) as a novel option in bladder cancer therapy

OR03  Issy Schiavi, St. George's University of London

Mycobacterial interactions promote Vγ9Vδ2 T cells to target and kill cancer cells

OR04  Jana Schoenfeld, Research Center Borstel, Germany

Uncovering epigenetic changes in early-stage MTBC-infected macrophages

Coffee Break


Resistance to new antitubercular drugs and clinical implications 

Chair: Francesca Conradie, Philip Supply


GL10  Claudio Köser, Cambridge University

The X(DR)-Files – I want to believe

OR05  Kurt Wollenberg, National Institute of Allergy and Infectious Diseases

Molecular evolutionary analysis of a clade of closely-related Delamanid-resistant Mycobacterium tuberculosis (M.tb) strains from Eastern Europe and Central Asia.

OR06  Annelies Van Rie, University of Antwerp

Bayesian probability of bedaquiline resistance to guide rifampicin-resistant tuberculosis treatment

OR07  Valeriu Crudu, State University of Medicine and Pharmacy, Chisinau, Moldova

Evolution of resistance to new drugs in high tuberculosis burden country.

OR08  Sonia Borrell, Swiss Tropical and Public Health Institute-University of Basel

Drug-specific differential culturability in diverse strains of Mycobacterium tuberculosis

OR09  Siavash Valafar, Chicago Medical School

Prognosis and Prevention of Antibiotic Resistance in Mycobacterium tuberculosis: the Isoniazid (INH) Case Study


Poster Session 1


Future of next generation sequencing

Chair: Kristin Kremer, Andrea Cabibbe


GL11 Philip Fowler, University of Oxford

Whole genome sequencing for tuberculosis: it works, how do we get it used more widely?

OR10  Vincent Rennie, Family Medicine and Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp

The MAGMA platform for global and equitable WGS-guided management of drug resistant TB and TB control

OR11  Maximilian Marin Department of Biomedical Informatics, Harvard Medical School

Analysis of the limited Mtb pan-genome reveals potential pitfalls of pan-genome analysis approaches

OR12  Christophe Sola, INSERM UMR1137

TB-ANNOTATOR: A scalable web application that allows in-depth analysis of very large sets of publicly available Mycobacterium tuberculosis complex genomes.

Coffee Break


Animal models to study mycobacterial infections 

Chair: Margarida Saraiva, Leen Rigouts


GL12 Pere-Joan Cardona Iglesias, Hospital Universitari Germans Trias i Pujol, Badalona

Mouse models to study TB pathogenesis

GL13 Nicola Lore, IRCCS San Raffaele Scientific Institute

Mouse models to study host-pathogens interaction in M.abscessuss lung infections

OR13 Maria Vidal Ramos, Unitat de Tuberculosi Experimental, Microbiology Dept. Germans Trias i Pujol Research Institute and Hospital (IGTP-HUGTIP), Badalona

Mycobacterium tuberculosis infecting Drosophila melanogaster: first insights of the new latent tuberculosis infection model.


Round Table: Bordering EU countries: Situation, challenges and way out (Availability and affordability of NGS technologies to control DR TB, Viral Diseases and AMR)

Chair: Silvia Bino, Hasan Hafizi, University Hospital for Lung diseases, Tirana


Round table discussion

Tuesday 27 June



Host pathogens interaction in NTMs 

Chair: Troels Lillebaek, Eva Sodja


GL14 Lucas BoeckUniversity Hospital Basel

Phenogenomic analyses: linking mycobacterial behaviours to molecular mechanisms

GL15  Stephen Leon Icaza, IPBS-Toulouse

The organoid revolution to assess mycobacterial pulmonary infections

OR14  Federico Di Marco, San Raffaele Scientific Institute, Emerging Bacterial Pathogens Unit

Single cells RNA sequencing of peripheral blood mononuclear cells reveals hyperinflammatory monocytes in patients with Mycobaterium abscessus pulmonary disease

OR15  Ivana Palucci, Catholic University of Sacred heart, Rome

Cysteamine/Cystamine exert anti-Mycobacterium abscessus activity alone or in combination with amikacin.

OR16  Francesca Nicola, San Raffaele Scientific Institute

The spatial distribution of type 1 and type 17 immune transcriptomics profiles in murine models of chronic lung infection by opportunistic pathogens

Coffee Break


Innovation in diagnostics

Chair: Christophe Sola, Paolo Miotto


GL16 Morten Ruhwald, FIND, Geneva

Future trends and innovation in diagnostics for TB - VIRTUAL

OR17 Onya Opota, Institute of Microbiology, Lausanne University Hospital and University of Lausanne

Nanomotion technology in combination with machine learning: a new approach for rapid antibiotic susceptibility test for Mycobacterium tuberculosis 

OR18  Leen Rigouts, Institute of Tropical Medicine, Antwerp, Belgium

Successful Myocbacterium tuberculosis culture isolation from spiked tongue swabs processed by the Kudoh-Ogawa or cetylpyridinium chloride methods.


OR19  Faridath Massou, Laboratoire de Reference des Mycobacteries

Deeplex Myc/TB directly on sputum detects more mixed infections and heteroresistance compared to culture-based whole genome sequencing.

OR20  Margaretha de Vos, FIND, Geneva

Diagnostic accuracy of upper airway swabs and saliva with Xpert MTB/RIF Ultra for the detection of tuberculosis in adults

OR21  Kristin Kremer, KNCV Tuberculosis Foundation

The simple one-step stool processing method to diagnose tuberculosis is robust enough for global scale up


Poster Session 2


Innovation in diagnostics (cont.)

Chair: Leen Rigouts, Richard Anthony


OR22 Emilyn Costa, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Tow

Evaluating DNA extraction commercial kits from Mycobacterium tuberculosis clinical primary liquid (MGIT) culture for downstream sequencing applications


OR23  Miguel Moreno, Biomedicine Institute of Valencia IBV-CSIC

The role of MIC shifts as early markers of treatment failure in tuberculosis

OR24  Tim Bull, St. George's University of London

Ph neutral anti-microbial peptide-based decontamination of samples enhances recovery in culture of low load Mycobacterium tuberculosis

OR25  Erik Svensson, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen

Detection of Mycobacterium tuberculosis and resistance mutations in different sample types using FluoroType MTBDR v2. A study from Germany and Denmark. 

OR26  Dmytro Butov, Kharkiv National Medical University 

Consideration of the results of the Xpert MTB/RIF method on the treatment outcome of patients with M\XDR pulmonary tuberculosis during the COVID-19 epidemic in Kharkiv region, Ukraine

Coffee Break

General Assembly


Wednesday 28 June


Session Non tuberculous mycobacteria, epidemiology and more 

Chair: Troels Lillabaek, Dorte Bek Folkvardsen


GL17 Victor Næstholt Dahl, Aarhus University Hospital

Global trends of pulmonary infections with nontuberculous mycobacteria

OR27  Margo Diricks, Research center Borstel

Exploring the plasmidome of non-tuberculous mycobacteria

OR28  Nils Wetzstein, Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main

Genomic landscape of M. avium complex in Central Germany

OR29  Xenia Iversen, International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark

Frozen in Time: Unlocking the History of Nontuberculous Mycobacteria

OR30  Sandra Salillas-Berges, Radboud University Medical Center

Rifampicin substituted by clofazimine in the recommended therapy of Mycobacterium avium pulmonary disease: a hollow-fibre model study

Coffee Break


Session Biology of Pathogen

Chair: Erik Svenson, Mireia Coscolla

OR36  Rina De Zwaan, National Institute for Public Health and the Environment

Next-generation sequencing  cluster typing; All single nucleotide polymorphisms are equal but some are more equal than others

OR31  Kerri Malone EMBL-EBI

Fine-scale evolution of Mycobacterium tuberculosis growth rate

OR32  Philip Supply, Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille

CRISPR-Cas molecular memory in Mycobacterium canettii reveals the putative ancestral environmental origin of M. tuberculosis

OR34  Sladjana Prisic, University of Hawaii at Manoa

From bad to worse: Does zinc limitation make M. tuberculosis more virulent?


Session Biology of Pathogen

Chair: Miguel Moreno, Violeta Valcheva


OR35  Melanie Grobbelaar Stellenbosch University

Evolution of drug resistance and treatment outcome within a longitudinal retrospective study – linking outcome to treatment.

OR33  Igor Mokrousov, St. Petersburg Pasteur Institute

Paleopathological and molecular evidence of tuberculosis in human skeletal remains from 18th-19th century Orthodox cemeteries in Irkutsk, Eastern Siberia

OR37  Joaquin Sanz, Universidad de Zaragoza - Instituto BIFI

Improving vaccine descriptions in model-based impact prognosis of new tuberculosis vaccines: removing arbitrariness and reducing bias.

OR38  Siavash Valafar, Chicago Medical School

Diversifying Evolution in Mycobacterium tuberculosis and Evasion of Molecular Diagnostics for Isoniazid (INH) Resistance is most prevalent in Asia


Poster Awards and Closing Ceremony

Chair: Daniela Maria Cirillo, Troels Lillebaek, Silva Tafaj


bottom of page